By Hendra Lukman 
A groundbreaking study analyzing health records from Wales has provided compelling evidence that the shingles vaccine may offer significant protection against the development of dementia. Researchers at Stanford Medicine, in collaboration with the Vienna University of Economics and Business, have identified a 20% reduction in dementia diagnoses among individuals who received the shingles vaccine compared to those who did not, over a seven-year period. This discovery, published in the prestigious journal Nature, supports a growing hypothesis within the scientific community: that certain viral infections impacting the nervous system could elevate the risk of dementia. If further validated, these findings suggest a readily available preventative measure against this debilitating neurological condition could already be in place.
The research team’s subsequent analysis, detailed in Cell, further explored the vaccine’s potential therapeutic benefits, indicating that it might also help to slow the progression of dementia in individuals already diagnosed with the condition. This dual-action possibility has ignited considerable optimism among researchers and public health officials alike, offering a beacon of hope in the ongoing battle against the global dementia epidemic.
The Viral Connection: Shingles, Chickenpox, and Neurological Health
Shingles, also known as herpes zoster, is a painful, blistering rash caused by the reactivation of the varicella-zoster virus (VZV). This is the same virus responsible for chickenpox. Following an initial infection, typically in childhood, VZV enters a dormant state within nerve cells, remaining in the body for life. In later years, particularly in older adults or individuals with compromised immune systems, the virus can reawaken, leading to the characteristic shingles outbreak.
The link between VZV and dementia has been a subject of growing scientific interest. For decades, dementia research has primarily focused on the accumulation of abnormal proteins, such as amyloid plaques and tau tangles, which are hallmarks of Alzheimer’s disease, the most common form of dementia. Despite extensive research, these efforts have yet to yield effective preventative or curative treatments. This lack of progress has prompted a shift in focus towards other potential contributors, including chronic viral infections that may cause cumulative damage to brain tissue over time.
A "Natural Experiment" in Wales: Unraveling Bias
Previous observational studies, which examined large health datasets, had hinted at a protective effect of the shingles vaccine against dementia. However, these studies were often hampered by a significant limitation: the inherent biases associated with vaccine recipients. Individuals who proactively choose to get vaccinated are often more health-conscious overall. They may adopt healthier lifestyles, including better dietary habits, increased physical activity, and more regular engagement with healthcare services. These confounding lifestyle factors, which are known to influence dementia risk, are notoriously difficult to quantify and control for in retrospective analyses of medical databases.
Dr. Pascal Geldsetzer, an assistant professor of medicine and senior author of the new study, highlighted this critical challenge. "All these associational studies suffer from the basic problem that people who go get vaccinated have different health behaviors than those who don’t," he explained. "In general, they are seen as not being solid enough evidence to make any recommendations on."
The landscape changed dramatically approximately two years ago when Dr. Geldsetzer identified a unique opportunity within Wales’s implementation of its shingles vaccination program. The specific rollout strategy of the vaccine, which utilized a live-attenuated (weakened) form of the VZV, created what researchers term a "natural experiment." This situation closely mimicked the rigor of a randomized controlled trial, largely circumventing the confounding biases present in earlier research.
Chronology of the Welsh Vaccination Program
The Welsh national shingles vaccination program commenced on September 1, 2013. The policy was meticulously designed to target specific age cohorts. Individuals who reached the age of 79 on this pivotal date were eligible to receive the vaccine within the following year. Subsequently, those who turned 78 the next year became eligible for a one-year period, and so forth. Crucially, individuals who were 80 years old or older on September 1, 2013, were deemed ineligible for the vaccine and would never become eligible under this policy.
This age-based eligibility criterion, tied to a precise cut-off date, created a clear demarcation. Individuals born just before September 1, 2013, were eligible, while those born just after were not, despite being only days or weeks older. This distinction allowed researchers to conduct a robust comparison between nearly identical groups of individuals, isolating the impact of vaccine eligibility.
Rigorous Analysis: Comparing Identical Groups
To leverage this unique circumstance, the research team meticulously analyzed the health records of over 280,000 older adults, aged between 71 and 88, who did not have a dementia diagnosis at the inception of the vaccination program. The focus of their analysis was narrowed to individuals whose birthdays placed them on either side of the eligibility line. Specifically, they compared individuals who turned 80 in the week preceding September 1, 2013, with those who turned 80 in the week following this date.
"We know that if you take a thousand people at random born in one week and a thousand people at random, born a week later, there shouldn’t be anything different about them on average," Dr. Geldsetzer elaborated. "They are similar to each other apart from this tiny difference in age."
The researchers reasoned that the desire for the shingles vaccine would be roughly equivalent across both groups. The pivotal difference, however, was that only the slightly younger cohort, those not yet 80 on September 1, 2013, were permitted to receive the vaccine under the established policy.
"What makes the study so powerful is that it’s essentially like a randomized trial with a control group — those a little bit too old to be eligible for the vaccine — and an intervention group — those just young enough to be eligible," Dr. Geldsetzer emphasized.
Quantifying Protection: Shingles and Dementia Outcomes
The research team then embarked on a seven-year longitudinal study, meticulously tracking the health outcomes of these comparable groups. By combining this outcome data with actual vaccination rates, they were able to estimate the protective effect of receiving the shingles shot. The data revealed that approximately half of the eligible individuals opted for vaccination, while very few from the ineligible group received it.
As anticipated, the vaccine demonstrated efficacy in reducing shingles incidence. Among those vaccinated, the rate of shingles declined by approximately 37% over the seven-year follow-up period, a figure consistent with data from clinical trials. It is important to note that the effectiveness of the live-attenuated vaccine can wane over time.
By 2020, when the study participants were in their late eighties, approximately one in eight individuals had developed dementia. However, within this cohort, those who had received the shingles vaccine exhibited a 20% lower likelihood of receiving a dementia diagnosis compared to their unvaccinated counterparts.
"It was a really striking finding," Dr. Geldsetzer stated. "This huge protective signal was there, any which way you looked at the data."
Ruling Out Alternative Explanations: A Robust Signal
The researchers undertook extensive efforts to identify and mitigate potential confounding factors that might explain the observed difference in dementia rates. They meticulously examined a wide array of demographic and health-related characteristics, finding that the eligible and ineligible groups were remarkably similar. Educational attainment levels were identical. Furthermore, individuals eligible for the shingles vaccine were no more likely to receive other vaccinations or preventive therapies, nor were they less likely to suffer from common comorbidities such as diabetes, heart disease, or cancer.
The singular, consistent difference identified between the two groups was the lower incidence of dementia diagnoses among those who had access to and received the shingles vaccine.
"Because of the unique way in which the vaccine was rolled out, bias in the analysis is much less likely than would usually be the case," Dr. Geldsetzer asserted.
Despite this strong initial finding, the team subjected their data to a variety of alternative analytical approaches. They explored different age windows and focused specifically on mortality data where dementia was listed as a cause of death. Regardless of the analytical method employed, the association between shingles vaccination and a reduced risk of dementia remained consistently robust.
"The signal in our data was so strong, so clear and so persistent," he reiterated.
Broader Implications: Prevention and Therapeutic Potential
Beyond its preventive role, the research team delved into whether the vaccine’s apparent benefits extended to individuals already exhibiting early signs of cognitive decline. Employing the same natural experiment framework, they investigated a spectrum of outcomes, ranging from mild cognitive impairment to advanced stages of dementia.
Many individuals diagnosed with dementia first experience a period of mild cognitive impairment (MCI), characterized by subtle deficits in memory and cognitive functions that do not yet impede independent living. The study revealed that individuals who received the shingles vaccine were less likely to receive an MCI diagnosis during a nine-year follow-up period compared to their unvaccinated counterparts.
Perhaps even more remarkably, the study examined individuals who already had dementia at the commencement of the Welsh vaccination program. In this group, the findings were particularly compelling. Those with dementia who received the shingles vaccine exhibited a significantly lower mortality rate from dementia in the subsequent nine years, as indicated on their death certificates. This suggests that the disease progression may have been considerably slower in the vaccinated individuals.
Across the entire cohort of 7,049 Welsh seniors who had dementia at the program’s start, nearly half died from dementia during the follow-up period. However, among those who received the shingles vaccine, only approximately 30% succumbed to dementia.
"The most exciting part is that this really suggests the shingles vaccine doesn’t have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia," Dr. Geldsetzer enthused.
Sex-Specific Effects and Unanswered Questions
An intriguing pattern emerged when the researchers analyzed outcomes based on sex. The protective effect of the shingles vaccine against dementia appeared to be substantially more pronounced in women than in men. Dr. Geldsetzer speculated that this disparity might be attributable to biological differences in immune responses or variations in how dementia manifests in men and women. On average, women tend to elicit stronger antibody responses following vaccination, and shingles occurs more frequently in women.
Despite the strong evidence, the precise mechanisms by which the vaccine confers protection against dementia remain an open question. Scientists are yet to definitively determine whether the vaccine operates by broadly stimulating the immune system, by reducing the frequency of VZV reactivation, or through an entirely different biological pathway.
Furthermore, it is unclear whether newer shingles vaccines, which employ recombinant protein technology and are more effective at preventing shingles outbreaks, would exhibit a similar or even enhanced effect on dementia risk.
Global Corroboration and the Push for a Randomized Trial
Dr. Geldsetzer expressed optimism that these findings will spur increased investment in this critical area of research. "At least investing a subset of our resources into investigating these pathways could lead to breakthroughs in terms of treatment and prevention," he urged.
In the past two years, his team has broadened their investigation, analyzing health records from other countries, including England, Australia, New Zealand, and Canada, where similar shingles vaccine rollout programs were implemented. The results from these international datasets have consistently mirrored the findings observed in Wales. "We just keep seeing this strong protective signal for dementia in dataset after dataset," he reported.
The ultimate goal for Dr. Geldsetzer and his team is to initiate a large-scale randomized controlled trial. Such a trial would provide the most definitive evidence regarding whether the shingles vaccine truly causes a reduction in dementia incidence. In a randomized controlled trial, participants would be randomly assigned to receive either the live-attenuated shingles vaccine or a placebo injection, allowing for a direct comparison of outcomes under controlled conditions.
"It would be a very simple, pragmatic trial because we have a one-off intervention that we know is safe," Dr. Geldsetzer stated.
He is currently seeking philanthropic support to fund this crucial research. This is particularly relevant as the live-attenuated vaccine, for which substantial evidence has been gathered through natural experiments, is now off-patent.
Dr. Geldsetzer also highlighted that such a trial could yield meaningful results relatively swiftly. The Welsh data demonstrated that the divergence in dementia rates between eligible and ineligible individuals began to emerge after approximately 18 months.
The research team from the Vienna University of Economics and Business played a significant role in this groundbreaking work. Funding for this study was generously provided by The Phil & Penny Knight Initiative for Brain Resilience, the Stanford Center for Digital Health, the National Institute on Aging (grant R01AG084535), the National Institute of Allergy and Infectious Diseases (grant DP2AI171011), and the Biohub, San Francisco. The comprehensive nature of the study, its rigorous methodology, and the promising implications for public health underscore the urgent need for continued research and investment in this promising avenue of dementia prevention and treatment.
